Furthermore, selective antagonists for MMP-2/MMP-9 or MMP-3 also suppressed the stimulatory effect of IL-17 on breast cancer invasion, although to a lesser extent than GM6001 (Figure 4). This evidence concerns the gene MMP9 and breast cancer.